Læknablaðið - 01.07.2014, Side 32

400 LÆKNAblaðið 2014/100
Heimildir
1. Saver J. Time is brain; quantified. Stroke 2006; 37: 263­6.
2. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ,
Demaerschalk BM, et al. American Heart Association
Stroke Council; Council on Cardiovascular Nursing;
Council on Peripheral Vascular Disease; Council on
Clinical Cardiology. Guidelines for the early management
of patients with acute ischemic stroke: a guideline
for healthcare professionals from the American Heart
Association/American Stroke Association. Stroke 2013;
44: 870­947.
3. Kleindorfer DO, Miller R, Moomaw CJ, Alwell K,
Broderick JP, Khoury J, et al. Designing a message for
public education regarding stroke: does FAST capture
enough stroke? Stroke 2007; 38: 2864­8.
4. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T,
Lindsberg PJ, Kaste M. Reducing in­hospital delay to 20
minutes in stroke thrombolysis. Neurology 2012; 79: 306­
13.
5. Johnston KC, Haley EC. Emergency imaging of the acute
stroke patient. J Neuroimaging 1997; 7: 111­7.
6. Hunter GJ, Hamberg LM, Ponzo JA, Huang­Hellinger
FR, Morris PP, Rabinov J, et al. Assessment of cerebral
perfusion and arterial anatomy in hyperacute stroke with
three­dimensional functional CT: early clinical results.
AJNR Am J Neuroradiol 1998; 19: 29­37.
7. Wintermark M, Reichhart M, Thiran JP, Maeder P,
Chalaron M, Schnyder P, et al. Prognostic accuracy of
cerebral blood flow measurement by perfusion computed
tomography, at the time of emergency room admission, in
acute stroke patients. Ann Neurol 2002; 51: 417­32.
8. Kidwell CS, Hsia AW. Imaging of the brain and cerebral
vasculature in patients with suspected stroke: advantages
and disadvantages of CT and MRI. Curr Neurol Neurosci
Rep 2006; 6: 9­16.
9. Josephson SA, Dillon WP, Smith WS. Incidence of contrast
nephropathy from cerebral CT angiography and CT
perfusion imaging. Neurology 2005; 64: 1805­6.
10. Shuaib A, Lee D, Pelz D, Fox A, Hachinski VC. The impact
of magnetic resonance imaging on the management of
acute ischemic stroke. Neurology 1992; 42: 816­8.
11. Lutsep HL, Albers GW, DeCrespigny A, Kamat GN,
Marks MP, Moseley ME. Clinical utility of diffusion­weig­
hted magnetic resonance imaging in the assessment of
ischemic stroke. Ann Neurol 1997; 41: 574­80.
12. Tissue plasminogen activator for acute ischemic stroke.
The National Institute of Neurological Disorders and
Stroke rt­PA Stroke Study Group. N Engl J Med 1995; 333:
1581­7.
13. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton
SA. Intravenous tissue­type plasminogen activator for
treatment of acute stroke: the Standard Treatment with
Alteplase to Reverse Stroke (STARS) study. JAMA 2000;
283: 1145­ 50.
14. Hill MD, Buchan AM. Methodology for the Canadian
Activase for Stroke Effectiveness Study (CASES). CASES
investigators. Can J Neurol Sci 2001; 28: 232­8.
15. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A,
Guidetti, et al. ECASS Investigators: Thrombolysis with
alteplase 3 to 4,5 hours after acute ischemic stroke. N Engl
J Med 2008; 359: 1317­29.
16. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millán M,
Muir K, et al. SITS investigators. Thrombolysis with alte­
plase 3­4.5 h after acute ischemic stroke (SITS­ISTR): an
observational study. Lancet 2008; 372: 1303­19.
17. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer
R, Broderick JP, et al. Association of outcome with early
stroke treatment: pooled analysis of ATLANTIS, ECASS,
and NINDS rt­PA stroke trials. Lancet 2004; 363: 768­74.
18. Kharitonova T, Thoren M, Ahmed N, Wardlaw JM,
von Kummer R, Thomassen L, et al. SITS Investigators:
Disappearing hyperdense middle cerebral artery sign
in ischemic stroke patients treated with intravenous
thrombolysis. J Neurol Neurosurg Psychiatry 2009; 80:
273­8.
19. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS,
Gobin YP, et al. Safety and efficacy of mechanical embolec­
tomy in acute ischemic stroke: results of the MERCI trial.
Stroke 2005; 36: 1432­38.
20. CAST: Randomised placebo­controlled trial of early
aspirin use in 20,000 patients with acute ischaemic stroke.
CAST (Chinese Acute Stroke Trial) Collaborative Group.
Lancet 1997; 349: 1641­9.
21. The International Stroke Trial (IST): A randomized trial
of aspirin, subcutaneous heparin, both, or neither among
19435 patients with acute ischaemic stroke. International
Stroke Trial Collaborative Group. Lancet 1997; 349: 1569­
81.
22. Gubitz G, Counsell C, Sandercock P, Signorini D.
Anticoagulants for acute ischaemic stroke. Cochrane
Database Syst Rev 2000; (2) : CD000024.
23. Becker K. Intensive care unit management of the stroke
patient. Neurol Clin 2000; 18: 439­54.
24. Kalafut MA, Saver JL. The acute stroke patient: the first six
hours. In: Cohen SN, ed. Management of ischemic stroke.
McGraw Hill, New York 2000: 17­52.
25. Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC,
et al. Hypertension and its treatment in the NINDS rt­PA
stroke trial. Stroke 1998; 29: 1504­9.
26. Berger L, Hakim AM. The association of hyperglycemia
with cerebral edema in stroke. Stroke 1986;17: 865­71.
27. Broderick JP, Hagen T, Brott T, Tomsick T. Hyperglycemia
and hemorrhagic transformation of cerebral infarcts.
Stroke 1995; 26: 484­7.
28. Reith J, Jorgensen HS, Pedersen PM, Nakayama H,
Raaschou HO, Jeppesen LL, et al. Body temperature
in acute stroke: relation to stroke severity, infarct size,
mortality, and outcome. Lancet 1996; 347: 422­5.
29. Castillo J, Davalos A, Noya M. Aggravation of acute ische­
mic stroke by hyperthermia is related to an excitotoxic
mechanism. Cerebrovasc Dis 1999; 9: 22­7.
30. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees
KR, et al. Hemorrhagic transformation in acute ischemic
stroke. The MAST­E study. MAST­E Group. Stroke 1999;
30: 1326­32.
31. Larrue V, von Kummer R, Muller A, Bluhmki E. Risk
factors for severe hemorrhagic transformation in ischemic
stroke patients treated with recombinant tissue plasm­
inogen activator: a secondary analysis of the European­
Australasian Acute Stroke Study (ECASS II). Stroke 2001;
32: 438­41.
32. Badjatia N, Rosand J. Intracerebral hemorrhage. Neuro­
logist 2005; 11: 311­24.
33. Collaborative overview of randomised trials of antip­
latelet therapy: III. reduction in venous thrombosis and
pulmonary embolism by antiplatelet prophylaxis among
surgical and medical patients. Antiplatelet Trialists‘
Collaboration. BMJ 1994; 308: 235­46.
34. Diener HC, Ringelstein EB, von Kummer R, Landgraf
H, Koppenhagen K, Harenberg J, et al. Prophylaxis of
thrombotic and embolic events in acute ischemic stroke
with low­molecular­weight heparin certoparin: results of
the PROTECT trial. Stroke 2006; 37: 139­44.
35. Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai
AA, Kase CS, et al; PREVAIL Investigators. The efficacy
and safety of enoxaparin versus unfractionated hep­
arin for the prevention of venous thromboembolism after
acute ischaemic stroke (PREVAIL Study): an open­label
randomized comparison. Lancet 2007; 369: 1347­55.
36. Schneider GH, von Helden GH, Franke R, Lanksch WR,
Unterberg A. Influence of body position on jugular venous
oxygen saturation, intracranial pressure and cerebral
perfusion pressure. Acta Neurochir Suppl (Wien) 1993;
59: 107­12.
37. Qureshi AI, Suarez JI, Bhardwaj A, Mirski M, Schnitzer
MS, Hanley DF, et al. Use of hypertonic (3%) saline/
acetate infusion in the treatment of cerebral edema: effect
on intracranial pressure and lateral displacement of the
brain. Crit Care Med 1998; 26: 440­446.
38. Norris J.W, Hachinski VC. High dose steroid treatment in
cerebral infarction. Br Med J (Clin Res Ed) 1986; 292: 21­3.
39. Vahedi K, Hofmeijer J, Juettler E, Vicaut E, George B,
Algra A, et al. DECIMAL, DESTINY, and HAMLET
investigators. Early decompressive surgery in malignant
infarction of the middle cerebral artery: a pooled analysis
of three randomized controlled trials. Lancet Neurol 2007;
6: 215­22.
40. Antithrombotic Trialists’ Collaboration Collaborative
meta­analysis of randomised trials of antiplatelet therapy
for prevention of death, myocardial infarction, and stroke
in high risk patients. BMJ 2002; 324: 71­86.
41. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins
R, Liu LS, et al. Indications for early aspirin use in acute
ischemic stroke: A combined analysis of 40 000 randomi­
zed patients from the chinese acute stroke trial and the
international stroke trial. On behalf of the CAST and IST
collaborative groups. Stroke 2000; 31: 1240­9.
42. Antiplatelet Trialists’ Collaboration Collaborative over­
view of randomised trials of antiplatelet therapy­­I:
Prevention of death, myocardial infarction, and stroke by
prolonged antiplatelet therapy in various categories of
patients. BMJ 1994; 308: 81­106.
43. Sudlow C. Dipyridamole with aspirin is better than
aspirin alone in preventing vascular events after ischaemic
stroke or TIA. BMJ 2007; 334: 901.
44. CAPRIE Steering Committee A randomised, blinded,
trial of clopidogrel versus aspirin in patients at risk of
ischaemic events (CAPRIE.) Lancet 1996; 348: 1329­39.
45. Sacco RL, Diener H­C, Yusuf S, Cotton D, Ounpuu S,
Lawton WA, et al; PRoFESS Study Group. Aspirin and
extended release dipyridamole versus clopidogrel for
recurrent stroke. N Engl J Med 2008; 359: 1238­51.
46. Zakarija A, Bandarenko N, Pandey DK, Auerbach A,
Raisch DW, Kim B, et al. Clopidogrel­associated TTP:
an update of pharmacovigilance efforts conducted by
independent researchers, pharmaceutical suppliers, and
the Food and Drug Administration. Stroke 2004; 35: 533­7.
47. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden
WE, et al. Clopidogrel and aspirin versus aspirin alone for
the prevention of atherothrombotic events. N Engl J Med
2006; 354: 1706­17.
48. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C,
Csiba L, Kaste M et al. MATCH investigators.Aspirin and
clopidogrel compared with clopidogrel alone after recent
ischaemic stroke or transient ischaemic attack in high­risk
patients (MATCH): randomised, double­blind, placebo­
controlled trial. Lancet 2004; 364: 331­7.
49. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL,
Fagan SC, et al. Guidelines for the Prevention of Stroke
in Patients With Stroke or Transient Ischemic Attack. A
Guideline for Healthcare Professionals From the American
Heart Association/American Stroke Association. Stroke
2011; 42: 227­76.
50. Hart RG, Pearce LA, Aguilar MI. Meta­analysis: antit­
hrombotic therapy to prevent stroke in patients who have
nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:
857­67.
51. Mant J, Hobbs FDR, Fletcher K on behalf of the BAFTA
investigators and the Midland Research Practices Network
(MidReC). Warfarin versus aspirin for stroke prevention in
an elderly community population with atrial fibrillation
(the Birmingham Atrial Fibrillation Treatment of the Aged
Study, BAFTA): a randomised controlled trial. Lancet 2007;
370: 493­503.
52. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman
S. Hemorrhagic complications of anticoagulant treat­
ment: the Seventh ACCP Conference on Antithrombotic
and Thrombolytic Therapy. Chest 2004; 126(Suppl 3):
287S–310S.
53. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J,
Oldgren J, Parekh A, et al. Dabigatran versus warfarin in
patients with atrial fibrillation. N Engl J Med. 2009; 361:
1139­51.
54 Wani M, Nga E, Navaratnasingham R. Should a patient
with primary intracerebral haemorrhage receive antiplate­
let or anticoagulant therapy? BMJ 2005; 331: 439­42.
55. Blood Pressure Lowering Treatment Trialists’
Collaboration Effects of different blood­pressure­lowering
regimens on major cardiovascular events: results of pro­
spectively­designed overviews of randomised trials.
Lancet 2003; 362: 1527­35.
56. Rashid P, Leonardi­Bee J, Bath P. Blood pressure reduction
and secondary prevention of stroke and other vascular
events: a systematic review. Stroke 2003; 34: 2741­8.
57. PROGRESS Collaborative Group Randomised trial of
a perindopril­based blood­pressure­lowering regimen
among 6,105 individuals with previous stroke or transient
ischaemic attack. Lancet 2001; 358: 1033­41.
58. Rothwell PM, Howard SC, Spence JD. Relationship
between blood pressure and stroke risk in patients with
symptomatic carotid occlusive disease. Stroke 2003; 34:
2583­90.
59. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low
dose combination treatment with blood pressure lowering
drugs: analysis of 354 randomised trials. BMJ 2003; 326:
1427.
60. Rothwell PM, Giles MF, Chandratheva A, Marquardt L,
Geraghty O, Redgrave JN, et al. Effect of urgent treatment
of transient ischaemic attack and minor stroke on early
recurrent stroke (EXPRESS study): a prospective popula­
tion­based sequential comparison. Lancet 2007; 370: 1432­
42.
61. Heart Protection Study Collaborative Group Effects of
cholesterol­lowering with simvastatin on stroke and other
major vascular events in 20536 people with cerebrovas­
cular disease or other high­risk conditions. Lancet 2004;
363: 757­67.
Y F I R L I T